<DOC>
	<DOCNO>NCT00901732</DOCNO>
	<brief_summary>Patients diagnose head and/or neck cancer commonly develop oral mucositis ( OM ) . The purpose study estimate effect Caphosol OM evaluate Caphosol effect clinical outcome include quality life , oral intake , swallow function pain .</brief_summary>
	<brief_title>Caphosol Reduction Mucositis Patients Receiving Radiation Therapy Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Diagnosed Head Neck Cancer patient plan Radiation therapy Have least one 10 predefined anatomic mucosal subsites view Age &gt; /= 18 year Life expectancy &gt; /= 6 month Planned RT head/neck Must able perform oral rinse Active infection oral cavity physiologic condition precludes use oral rinse Hypersensitivity Caphosol ingredient Presence mucosal ulceration baseline Poorly control hypertension , DM serious medical/psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Caphosol</keyword>
	<keyword>Oral Mucositis</keyword>
	<keyword>Eusa Pharma</keyword>
	<keyword>Moffitt Cancer Center</keyword>
</DOC>